BIOCARDIA®

Nasdaq: BCDA

www.biocardia.com

Recent Stock Price (4/30/20) - $4.75
52 Week Range - $2.10-$17.50
Market Capitalization - $32.6M
Shares Outstanding - 6.9M
Fiscal Year End - December 31st

BioCardia, Inc. is developing regenerative biologic therapies to treat cardiovascular disease. Autologous CardiAMP and NK1+ Allogenic cell therapies are the Company's biotherapeutic product candidates in clinical development. The Company's approved products include the Helix™ transendocardial delivery system and its steerable guide and sheath catheter portfolio.

INVESTMENT HIGHLIGHTS

- Over $10B in total addressable market
- Truly unmet clinical need with great clinical promise seen in early results
- Unique patented technology
- Large revenue potential in global markets
- Expanding body of clinical research
- FDA cleared devices
- Clean capital structure
- Stable financials
- Medicare reimbursed trials
- Large corporate partners
- History of meeting milestones

Recently announced positive preclinical results for its "off the shelf" CardiAllo ™ program. The company intends to submit an IND to treat Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19.

Advancing the Best of Both Worlds: Autologous and Allogenic Cell Based Therapies

A patient's own (autologous) CardiAMP cell therapy in Heart Failure and Chronic Ischemia (BCDA-01, BCDA-02):

- 1.6 million patients in the USA alone with no curative therapies
- Regulated and manufactured as a procedure kit with anticipated low cost of goods and long shelf life
- For both leading indications, CardiAMP fits into standard interventional cardiology device channels
- Most components approved in EU and/or USA, but not for cardiovascular therapeutic usage

A young donor's (allogenic) CardiALLO cell therapy for patients whose own cells don't pass potency assay (BCDA-03):

- "The stem cells that respond to pain and inflammation"
- Treats patients not possible to be treated with CardiAMP
- Potential orphan indication
- "Off the shelf" cell therapy
- Leverages delivery system



- The 1st cardiac cell therapy that combines a pre-procedural assay, point of care cell processing system and transendocardial delivery system.
- The 1st U.S. pivotal trial for any cardiac cell therapy.
- The 1st U.S. cardiac cell therapy program supported with Medicare reimbursement.
- 74 patients enrolled and the independent data safety monitoring board recommends no changes to trial design Q1 2020.

1.8 Million+ Patients Per Year with Heart Failure and Chronic Myocardial Ischemia and a High Value Therapy

Program	Indication	Reachable market USA	Potential Market Size
Autologous CardiAMP BCDA-01	Ischemic Heart Failure	1,400,000	$28 Billion
Autologous CardiAMP BCDA-02	Chronic Myocardial Ischemia	200,000	$4 Billion
NK1+ Allogenic CardiALLO BCDA-03	Ischemic Heart Failure	200,000	$6 Billion
	TOTAL	1.8 M	$38 Billion

MEDICARE IS REIMBURSING BOTH CARDIAMP HF AND CARDIAMP CMI PROGRAMS SUBSTANTIALLY REDUCING COST OF CLINICAL DEVELOPMENT

Creating Value: Anticipated Milestones 2020

- Q2 Phase III pivotal trial commencement/first sites activated in CardiAMP Chronic Myocardial Ischemia (CMI) Trial, a second Phase III pivotal program for CardiAMP (BCDA-02)
- Q2 FDA acceptance of Investigational New Drug Application for CardiALLO Neurokinin-1 Receptor Positive Mesenchymal Stem Cell Therapy (BCDA-03), the Company's second therapeutic platform
- Q4 FDA acceptance of Investigational New Drug application for BDCA-03 for the potential treatment of ARDS as a result of COVID-19 infection
- Q4 Pre-specified Data Safety Monitoring Board Review of all patients enrolled, including futility analysis, based on sixty (60) patients that will have reached the primary one-year follow- up endpoint at the time of analysis (BCDA-01)
- Q4 Pre-specified Data Safety Monitoring Board Review of safety data from roll-in cohort in CardiAMP CMI Trial (BCDA-02)

Hospital Partners Include

Yale-New Haven Hospital · Mayo Clinic · School of Medicine and Public Health, University of Wisconsin-Madison · Texas Heart Institute · Yale University School of Medicine · UF College of Medicine, University of Florida · Stanford School of Medicine, Stanford University Medical Center · Cedars-Sinai · Weill Cornell Medicine · Morton Plant Mease, BayCare Health System · Sutter Health CPMC · Keck School of Medicine of USC · NYU School of Medicine, NYU Langone Medical Center

BioCardia, Inc.
Peter Altman, PhD, CEO
125 Shoreway Rd. Ste. B
San Carlos, CA 94070
650-221-0121
info@BioCardia.com
www.biocardia.com

CORE IR
Tristan Traywick,
Investor Relations
377 Oak Street
Garden City, NY 11530
516-222-2560
tt@coreir.com